ArticleKidney international2016
Patients with primary membranous nephropathy are at high risk of cardiovascular events.
Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 77 citations in OpenAlex.
- Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Thromboembolism in the left main coronary artery of a patient with membranous nephropathy: a case report.Frontiers in cardiovascular medicine · 2026Article
- Autophagy in the Pathogenesis of Membranous Nephropathy.Kidney medicine · 2025Review
- Antigens in membranous nephropathy: discovery and clinical implications.Nature reviews. Nephrology · 2025Review
- Trans-ethnic Mendelian randomization analysis of membranous nephropathy and peripheral artery disease with mediating effects of thrombomodulin.Scientific reports · 2025Article
- Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants.Kidney international reports · 2025Review
- Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort.Clinical kidney journal · 2025Article
- Higher triglyceride-glucose index is associated with severe proteinuria and decreased renal function in patients with primary membranous nephropathy.BMC nephrology · 2025Article
- Analysis of Cardiovascular and Cerebrovascular Prognosis and Risk Factors in Patients with Primary Membranous Nephropathy.Kidney360 · 2025Article
- Article
- The risk of thromboembolic events in patients with nephrotic syndrome and relatively high albumin levels: a study over 10 years.BMC nephrology · 2024Article
- Effect of immunosuppressive agents on clinical outcomes in idiopathic membranous nephropathy.Kidney research and clinical practice · 2024Article
- Routine cardiac biomarkers for the prediction of incident major adverse cardiac events in patients with glomerulonephritis: a real-world analysis using a global federated database.BMC nephrology · 2024Article
- Membranous nephropathy: pathogenesis and treatments.MedComm · 2024Review
- Stroke associated with primary membranous nephropathy in a young adult: Case reportBiomedica : revista del Instituto Nacional de Salud · 2024Article
- Cardiovascular Risk in Patients With Glomerular Disease: A Narrative Review of the Epidemiology, Mechanisms, Management, and Patient Priorities.Canadian journal of kidney health and disease · 2024Review
- The thickness of glomerular basement membrane predicts complete remission in primary membranous nephropathy.Renal failure · 2023Article
- Article
- Thromboembolism in nephrotic syndrome: controversies and uncertainties.Research and practice in thrombosis and haemostasis · 2023Review
- Risk factors of venous thromboembolism in anti-PLA2R-positive and negative primary membranous nephropathy.Clinical kidney journal · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 4 countries.
Funding
Abstract
Here we conducted a retrospective study to examine the risk of cardiovascular events (CVEs) relative to that of end-stage renal disease (ESRD) in patients with primary membranous nephropathy, in a discovery cohort of 404 patients. The cumulative incidence of CVEs was estimated in the setting of the competing risk of ESRD with risk factors for CVEs assessed by multivariable survival analysis. The observed cumulative incidences of CVEs were 4.4%, 5.4%, 8.2%, and 8.8% at 1, 2, 3, and 5 years respectively in the primary membranous nephropathy cohort. In the first 2 years after diagnosis, the risk for CVEs was similar to that of ESRD in the entire cohort, but exceeded it among patients with preserved renal function. Accounting for traditional risk factors and renal function, the severity of nephrosis at the time of the event (hazard ratio 2.1, 95% confidence interval 1.1 to 4.3) was a significant independent risk factor of CVEs. The incidence and risk factors of CVEs were affirmed in an external validation cohort of 557 patients with primary membranous nephropathy. Thus early in the course of disease, patients with primary membranous nephropathy have an increased risk of CVEs commensurate to, or exceeding that of ESRD. Hence, reduction of CVEs should be considered as a therapeutic outcome measure and focus of intervention in primary membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.